NL300996I2 - Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout - Google Patents

Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout Download PDF

Info

Publication number
NL300996I2
NL300996I2 NL300996C NL300996C NL300996I2 NL 300996 I2 NL300996 I2 NL 300996I2 NL 300996 C NL300996 C NL 300996C NL 300996 C NL300996 C NL 300996C NL 300996 I2 NL300996 I2 NL 300996I2
Authority
NL
Netherlands
Prior art keywords
naldemedine
solvate
salt
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NL300996C
Other languages
English (en)
Dutch (nl)
Other versions
NL300996I1 (nl
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NL300996I1 publication Critical patent/NL300996I1/nl
Publication of NL300996I2 publication Critical patent/NL300996I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL300996C 2005-05-25 2019-06-26 Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout NL300996I2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2006065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体

Publications (2)

Publication Number Publication Date
NL300996I1 NL300996I1 (nl) 2019-07-03
NL300996I2 true NL300996I2 (nl) 2019-07-30

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300996C NL300996I2 (nl) 2005-05-25 2019-06-26 Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout

Country Status (20)

Country Link
US (4) US8084460B2 (show.php)
EP (1) EP1889848B8 (show.php)
JP (1) JP4323547B2 (show.php)
KR (1) KR100912782B1 (show.php)
CN (1) CN101228172B (show.php)
AU (1) AU2006250390B2 (show.php)
BE (1) BE2019C533I2 (show.php)
BR (1) BRPI0610343B8 (show.php)
CA (1) CA2609733C (show.php)
DK (1) DK1889848T3 (show.php)
ES (1) ES2525215T3 (show.php)
FR (1) FR19C1042I2 (show.php)
HU (1) HUS1900034I1 (show.php)
MX (1) MX2007014588A (show.php)
NL (1) NL300996I2 (show.php)
PL (1) PL1889848T3 (show.php)
PT (1) PT1889848E (show.php)
RU (1) RU2403255C2 (show.php)
TW (1) TWI311056B (show.php)
WO (2) WO2006126529A1 (show.php)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
CA2734333A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
WO2011142620A2 (en) * 2010-05-13 2011-11-17 Green Cross Corporation (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants
BR112013011593B1 (pt) * 2010-11-12 2022-02-22 Shionogi & Co., Ltd Sal de ácido p-toluenossulfônico
ES2903149T3 (es) 2012-05-14 2022-03-31 Shionogi & Co Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado
CN110325178B (zh) * 2016-12-26 2022-05-13 盐野义制药株式会社 改善含量均一性的制剂的制造方法
EP3773573B1 (en) 2018-04-12 2026-03-18 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
JP7437490B2 (ja) 2019-10-16 2024-02-22 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
EP4062973A4 (en) 2019-11-20 2023-11-29 Shionogi & Co., Ltd 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) * 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
AU686203B2 (en) 1993-07-23 1998-02-05 Toray Industries, Inc. Morphinan derivative and medicinal use
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
KR19990077125A (ko) 1996-01-10 1999-10-25 파올로 비지, 엔리꼬 카쭐라니 헤테로고리-축합 모르핀 유도체 (ⅱ)
WO2001002375A1 (en) 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
WO2001037785A2 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
AU2001259458B2 (en) * 2000-05-05 2006-09-14 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist compositions and dosage forms
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
WO2001085257A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
ATE292625T1 (de) * 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
DE60135016D1 (de) * 2000-11-22 2008-09-04 Toray Industries Indolderivate und deren verwendung in medikamenten
KR100901402B1 (ko) * 2001-08-23 2009-06-05 엔.브이.오가논 14-히드록시노르모르피논 유도체의 제조 방법
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
CN1288158C (zh) 2002-07-11 2006-12-06 东丽株式会社 用于预防恶心和呕吐的治疗剂或预防剂
JP2006502190A (ja) 2002-09-18 2006-01-19 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ デルタ−オピオイド受容体に選択的なオピエート類似物
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
JP5266492B2 (ja) 2004-05-28 2013-08-21 ヒューマン バイオモレキュラル リサーチ インスティテュート 代謝安定性鎮痛薬、疼痛薬物療法及び他の物質の合成
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
BR112013011593B1 (pt) 2010-11-12 2022-02-22 Shionogi & Co., Ltd Sal de ácido p-toluenossulfônico

Also Published As

Publication number Publication date
US8084460B2 (en) 2011-12-27
FR19C1042I2 (fr) 2020-06-19
PL1889848T3 (pl) 2015-04-30
EP1889848B1 (en) 2014-10-15
BE2019C533I2 (show.php) 2025-12-10
US8536192B2 (en) 2013-09-17
MX2007014588A (es) 2008-01-24
CN101228172A (zh) 2008-07-23
US20120135978A1 (en) 2012-05-31
TW200726470A (en) 2007-07-16
CA2609733C (en) 2011-07-19
NL300996I1 (nl) 2019-07-03
FR19C1042I1 (show.php) 2019-08-09
CN101228172B (zh) 2013-04-03
EP1889848A1 (en) 2008-02-20
AU2006250390A1 (en) 2006-11-30
BRPI0610343B1 (pt) 2020-03-10
BRPI0610343B8 (pt) 2021-05-25
PT1889848E (pt) 2014-12-09
KR100912782B1 (ko) 2009-08-18
BRPI0610343A2 (pt) 2010-06-15
HUS1900034I1 (hu) 2019-07-29
KR20080014791A (ko) 2008-02-14
TWI311056B (en) 2009-06-21
JPWO2006126637A1 (ja) 2008-12-25
ES2525215T3 (es) 2014-12-19
EP1889848B8 (en) 2014-12-17
DK1889848T3 (en) 2014-12-01
US20090203723A1 (en) 2009-08-13
AU2006250390B2 (en) 2010-07-08
USRE46375E1 (en) 2017-04-25
RU2403255C2 (ru) 2010-11-10
CA2609733A1 (en) 2006-11-30
EP1889848A4 (en) 2011-08-10
JP4323547B2 (ja) 2009-09-02
WO2006126637A1 (ja) 2006-11-30
WO2006126529A1 (ja) 2006-11-30
RU2007148412A (ru) 2009-06-27
USRE46365E1 (en) 2017-04-11

Similar Documents

Publication Publication Date Title
NL300996I2 (nl) Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout
NL301261I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL301042I1 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I2 (nl) crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301004I2 (nl) Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301020I2 (nl) Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat
FIC20240039I1 (fi) Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NL300974I2 (nl) Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301104I2 (nl) Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat.
NO2021018I1 (no) kabotegravir eller et farmasøytisk akseptabelt salt eller solvat derav
NL301106I2 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301057I2 (nl) Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL300990I2 (nl) Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan
NL300913I2 (nl) Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
NL300863I2 (nl) Palbociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300887I2 (nl) Tofacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder tofacitinibcitraat
NL300865I2 (nl) Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
DK1963369T3 (da) Il-21-antagonister
FR2876829B1 (fr) Le tableau anime multisensoriel
EP1852117A4 (en) PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
ATE386163T1 (de) Gleisbaumaschine
FI20041392A0 (fi) Hitsauslaite